Novo-Nordisk A/S
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
公司地址 Novo Alle 1, Bagsvaerd, DNK, 2880
電話號碼 +45 44448888
傳真號碼 --
公司網頁 https://www.novonordisk.com
員工數量 69505
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Thilde Hummel Bogebjerg Executive Vice President, Enterprise IT and Quality -- 04/02/2026
Ms. Elin Jager Senior Vice President, Chief of Staff and Corporate Strategy and Sustainability -- 04/02/2026
Mr. Jamey Millar Executive Vice President, Us Operations -- 04/02/2026
Mr. Hong Chow Executive Vice President, Product and Portfolio Strategy -- 04/02/2026
Ms. Tania Sabroe Executive Vice President, People, Organisation and Corporate Affairs -- 04/02/2026
Mr. Martin Holst Lange Executive Vice President, Research and Development and Chief Scientific Officer -- 04/02/2026
Mr. Emil Kongshoj Larsen Executive Vice President, International Operations -- 04/02/2026
Mr. Kasper Bodker Mejlvang Executive Vice President, CMC and Product Supply -- 04/02/2026
Mr. Ludovic Helfgott Executive Vice President, Product and Portfolio Strategy -- 04/02/2026
Mr. Maziar Mike Doustdar President and Chief Executive Officer -- 04/02/2026
Mr. Karsten Munk Knudsen Executive Vice President and Chief Financial Officer DKK 9.10M 04/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Stephan Engels Independent Director 04/02/2026
Ms. Britt Meelby Jensen Director 04/02/2026
Ms. Mette Bojer Jensen Director 04/02/2026
Mr. Kasim Kutay Director 04/02/2026
Dr. Cees de Jong Vice Chairman of the Board 04/02/2026
Ms. Liselotte Hyveled Director 04/02/2026
Ms. Elisabeth Dahl Christensen Director 04/02/2026
Mr. Lars Rebien Sorensen Chairman of the Board 04/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:31)
代號 名稱 佔比% ▼ 持有日期
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
BCATBlackRock Capital Allocation Term ord<0.000001%31/12/2025
BDVLiShares Disciplined Vol Eq Act ETF<0.000001%13/02/2026
BDYNiShares Dynamic Equity Active ETF<0.000001%30/06/2025
BFREWestwood LBRTY Global Equity ETF<0.000001%24/02/2026
BGYBlackRock Enhanced Intl Div Trust<0.000001%31/12/2025
BIDDiShares International Dividend ActiveETF<0.000001%11/02/2026
CGGOCapital Group Global Growth Equity ETF<0.000001%30/09/2025
CRTCXtrackers US National Crtcl Techs ETF<0.000001%16/02/2026
CZARThemes Natural Monopoly ETF<0.000001%13/01/2026
DIVSGuinness Atkinson Dividend Builder ETF<0.000001%31/07/2025
DMCYDemocracy International<0.000001%10/02/2026
DMXFiShares ESG Advanced MSCI EAFE ETF<0.000001%28/02/2026
ECATBlackRock ESG Capital Allocation Term<0.000001%31/12/2025
EFAViShares MSCI EAFE Min Vol Factor ETF<0.000001%25/02/2026
ETFTFundsmith Equity ETF<0.000001%06/02/2026
ETGEV Tax Adv Global Dividend Inc<0.000001%30/09/2025
ETOEV Tax Adv Global Div Opps<0.000001%30/09/2025
EXUSNomura Focused International Core ETF<0.000001%01/08/2025
FFDIFidelity Fundamental Developed Intl ETF<0.000001%17/07/2025
  1    2    3    4    5    6    7   8    9    10  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.